IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL5.67▲ 0.45% USD/MXN18.52▼ 0.42% USD/CLP994.16▼ 0.13% USD/COP3,302▲ 0.70% USD/PEN3.40▼ 0.16% USD/ARS1,544▼ 0.11% USD/UYU40.59▲ 2.33% USD/PYG6,196▲ 2.33% USD/BOB11.59▼ 0.37% USD/DOP60.59▲ 1.85% USD/CRC442.74▼ 0.10% USD/GTQ7.64▲ 2.06% USD/HNL26.91▲ 2.15% USD/NIO36.62▲ 2.73% USD/VES909.35▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.69▲ 1.39% USD/TTD6.75▲ 1.58% EUR/BRL6.25▲ 0.93% BRENT 95.84 ▲ 0.02% WTI 88.56 ▼ 0.20% IRON ORE 161.91 — — COPPER 6.09 ▼ 1.50% GOLD 3,886 ▲ 0.03% SILVER 49.12 ▼ 1.70% SOY 1,232 ▲ 0.37% CORN 445.50 ▲ 0.68% WHEAT 593.25 ▲ 1.54% COFFEE 279.25 ▼ 0.34% SUGAR 18.40 ▲ 0.99% ORANGE JUICE 136.85 ▼ 2.91% COTTON 79.02 ▲ 0.44% COCOA 5,123 ▲ 1.13% BEEF 224.80 ▲ 2.70% CATTLE 335.35 ▼ 0.10% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 ▲ 1.34% VALE3 63.50 ▼ 0.70% ITUB4 42.27 ▲ 1.42% BBDC4 14.52 ▲ 1.40% ABEV3 15.79 ▲ 0.25% BBAS3 15.10 ▼ 2.45% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 ▼ 2.27% RENT3 30.07 ▲ 1.66% AZZA3 15.91 ▼ 5.86% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 ▼ 1.63% RANI3 8.18 — 0.00% CSNA3 3.72 ▼ 12.06% IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL 5.67 ▲ 0.45% USD/MXN 18.52 ▼ 0.42% USD/CLP 994.16 ▼ 0.13% USD/COP 3,302 ▲ 0.70% USD/PEN 3.40 ▼ 0.16% USD/ARS 1,544 ▼ 0.11% USD/UYU 40.59 ▲ 2.33% USD/PYG 6,196 ▲ 2.33% USD/BOB 11.59 ▼ 0.37% USD/DOP 60.59 ▲ 1.85% USD/CRC 442.74 ▼ 0.10% USD/GTQ 7.64 ▲ 2.06% USD/HNL 26.91 ▲ 2.15% USD/NIO 36.62 ▲ 2.73% USD/VES 909.35 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 1.39% USD/TTD 6.75 ▲ 1.58% EUR/BRL 6.25 ▲ 0.93% BRENT 95.84 ▲ 0.02% WTI 88.56 ▼ 0.20% IRON ORE 161.91 — — COPPER 6.09 ▼ 1.50% GOLD 3,886 ▲ 0.03% SILVER 49.12 ▼ 1.70% SOY 1,232 ▲ 0.37% CORN 445.50 ▲ 0.68% WHEAT 593.25 ▲ 1.54% COFFEE 279.25 ▼ 0.34% SUGAR 18.40 ▲ 0.99% ORANGE JUICE 136.85 ▼ 2.91% COTTON 79.02 ▲ 0.44% COCOA 5,123 ▲ 1.13% BEEF 224.80 ▲ 2.70% CATTLE 335.35 ▼ 0.10% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 ▲ 1.34% VALE3 63.50 ▼ 0.70% ITUB4 42.27 ▲ 1.42% BBDC4 14.52 ▲ 1.40% ABEV3 15.79 ▲ 0.25% BBAS3 15.10 ▼ 2.45% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 ▼ 2.27% RENT3 30.07 ▲ 1.66% AZZA3 15.91 ▼ 5.86% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 ▼ 1.63% RANI3 8.18 — 0.00% CSNA3 3.72 ▼ 12.06%
since 2009
Saturday, November 14, 2026

Covid-19 Brazil

Peru Halts Chinese Coronavirus Vaccine Trials After Volunteer Develops Neurological Problems

By · · 2 min read

RIO DE JANEIRO, BRAZIL – Peru has temporarily suspended clinical trials of a Covid-19 vaccine made by Chinese drug giant Sinopharm after detecting neurological problems in one of its test volunteers.

The National Institute of Health said on Friday that it had decided to interrupt the trial after a volunteer had difficulty moving their arms, according to local media.

“Several days ago we signalled, as we are required, to the regulatory authorities that one of our participants (in trials) presented neurological symptoms which could correspond to a condition called Guillain-Barre syndrome,” said chief researcher German Malaga in comments to the press.

Free daily brief — no card needed
Get every Brazil story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.
Peru has temporarily suspended clinical trials of a Covid-19 vaccine made by Chinese drug giant Sinopharm after detecting neurological problems in one of its test volunteers.
Peru has temporarily suspended clinical trials of a Covid-19 vaccine made by Chinese drug giant Sinopharm after detecting neurological problems in one of its test volunteers.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Guillain-Barre syndrome is a rare and non-contagious disorder which affects the movement of the arms and legs. Peru declared a temporary health emergency in five regions in June last year following multiple cases.

In the 1970s a campaign to inoculate Americans against a supposedly devastating strain of swine flu ground to a halt after some 450 of those vaccinated developed the syndrome, which can also cause paralysis.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Exxon gets Guyana approval for a gas project”

Peru’s clinical trials for the Sinopharm vaccine were due to conclude this week, after testing around 12,000 people.

If they are successful – which won’t be known until mid-2021 – the Peruvian government was expected to buy up to 20 million doses to inoculate two-thirds of its population.

60,000 across the globe have already taken the Sinopharm vaccine, including volunteers in Argentina, Russia and Saudi Arabia.

Peru has one of the world’s highest per capita death rate from the virus, which as of Friday had caused 36,499 fatalities and 979,111 infections.

 

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.